Denver, CO | May 5, 2026 — AOA Dx, Inc. (“AOA”), a diagnostics company focused on transforming the early identification of ovarian cancer, today announced the enrollment of the first participant in its APEX study, a prospective, multi-site study being conducted across the United States and Europe, designed to expand the company’s industry-leading biobank of women presenting with vague abdominal symptoms.
The APEX study represents a major operational milestone for AOA, reflecting the strength, scalability, and maturity of the company’s fully integrated, in-house clinical operations organization. The study further deepens AOA’s proprietary repository of high-quality biospecimens from women experiencing symptoms that frequently overlap across multiple gynecologic and abdominal conditions.
“Enrolling the first patient in APEX is a clear demonstration of the clinical execution engine we have built at AOA,” said Oriana Papin-Zoghbi, Chief Executive Officer of AOA Dx. “APEX is a strategic study that reinforces our ability to rapidly design, activate, and operate complex, multi-site clinical programs entirely in-house, while continuing to build long-term data assets that support both our core focus and future indication expansion within this clinically important population.”
APEX focuses on the collection of blood samples from women experiencing non-specific abdominal and pelvic symptoms — a population that represents a significant diagnostic challenge and an area of substantial unmet clinical need. By systematically capturing data and biospecimens from this group across multiple geographies, AOA is strengthening the foundation for a broader diagnostic platform that can address multiple indications where symptom overlap and delayed diagnosis remain persistent problems.
“The ability to independently execute studies like APEX — on time, at scale, and with rigor — is a competitive advantage,” added Anna Jeter, Chief Regulatory Officer at AOA Dx. “This milestone reflects not only the depth of our clinical infrastructure, but also the strategic foresight to build assets that support long-term platform expansion within women’s health.”
About AOA Dx
AOA Dx is transforming early cancer detection with its proprietary platform, a first-of-its-kind, multi-omics liquid biopsy that integrates lipids, metabolites, proteins and clinical data using advanced machine learning. The company’s lead test, AKRIVIS GD™, is designed to detect ovarian cancer early in symptomatic women, addressing a critical diagnostic gap in one of the deadliest cancers affecting women.
Based in Denver, Colorado, AOA Dx is led by an experienced team of scientists and industry veterans. The lab specializes in multi-omics analysis across lipidomics, metabolomics, and proteomics, powered by high-resolution mass spectrometry. By converting discovery-level data into validated, targeted assays, the platform enables repeatable, clinically scalable diagnostics with strong IP and regulatory pathways.
Media Contact:
Ariel Kramer
Klover Communications
ariel@klovercommunications.com